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Abstract: Tuberculosis (TB) diagnosis is increasingly based on the detection of Mycobacterium
tuberculosis complex (MTBC) DNA in sputum using molecular diagnostic tests as the first test for
diagnosis. However, sputum can be difficult to obtain in children, patients without productive
cough, and the elderly and approaches testing non-sputum samples are needed. We evaluated
whether TB can be detected from the oral mucosa of patients with TB. Adults with presumptive TB
were examined using culture, Xpert MTB/RIF, smear microscopy and X-Rays. Oral mucosa swabs
collected on PrimeStore-MTM, stored at room temperature if tested within 30 days or at −20 ◦C if
examined at a later time. RT-PCR was performed to detect M. tuberculosis DNA. Eighty patients had
bacteriologically-confirmed TB, 34 had bacteriologically-negative TB (negative tests but abnormal
X-rays) and 152 were considered not to have TB (not TB). Oral swabs RT-PCR were positive in 29/80
(36.3%) bacteriologically-confirmed, 9/34 (26.5%) bacteriologically-negative and 29/152 (19.1%) not
TB. The yield varied among samples stored for less and more than 30 days (p = 0.013) from 61%
(11/18) and 29% (18/62) among bacteriologically confirmed, and 30.8% (4/13) and 23.8% (5/21) among
bacteriologically-negative participants. Among not TB patients, the specificity was 80.9% (123/152),
being 78.3% (18/23) among samples stored less than 30 days and 81.4% (105/129) among samples
stored for more than 30 days (p = 0.46). The detection of M. tuberculosis in oral mucosa samples is
feasible, but storage conditions may affect the yield.
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1. Introduction
Tuberculosis (TB) causes 10 million annual cases and is the leading cause of adult death from
an infectious agent [1]. In the last decade, its diagnosis is increasingly based on the detection of
Mycobacterium tuberculosis complex (MTBC) DNA using molecular diagnostic assays, after the World
Health Organization (WHO) recommendation to use these assays as the first test for diagnosis for
people with presumptive TB. Most patients are tested using sputum, but these specimens can be
difficult to obtain in young children and the elderly, and in patients without productive cough [2].
Recent studies have reported it is possible to recover MTBC DNA from the oral cavity of individuals
with bacteriologically confirmed TB [3–5]. Although this is an unusual location, MTBC was frequently
detected from the tonsils and adenoids of individuals undergoing tonsillectomies in the 19th and 20th
centuries, and was proposed as a method to assess the prevalence of TB in the 1930s, and thus the
presence of MTBC in the mouth is biologically plausible [6].
In this study, we explored whether patients undergoing routine investigations for TB diagnosis
carry MTBC DNA in their oral cavity, to assess its potential as an adjunct test for the diagnosis of TB.
2. Materials and Methods
This was a cross sectional study of consecutive adults attending the ambulatory services of the
Institute of Phthisiopneumology “Chiril Draganiuc”, Chisinau, Moldova, with a clinical diagnosis
of presumptive TB. All patients attending the center were examined with light sputum smear
microscopy (Ziehl-Neelsen), liquid culture (BACTEC MGIT 960 TB system, BD, Franklin Lakes, NJ,
USA) and X-rays, following the local diagnostic algorithm. X-rays were read by radiologists of the
institute and individuals with abnormal X-rays were tested with Xpert MTB/RIF (GX). Participants
were classified as bacteriologically-confirmed if the smear-microscopy, GX or culture were positive;
bacteriologically-negative TB if the laboratory tests were negative but the X-Rays or/and clinically were
considered compatible with TB, and not TB if the laboratory tests were negative and the X-rays were
considered to be normal.
Oral mucosa samples were collected before initiation of TB treatment and at the time they attended
the laboratory to provide clinical specimens for examination. Samples were collected using flocked
swab collection devices (PrimeSwab, Longhorn Vaccines and Diagnostics, San Antonio, TX, USA) by
brushing the swab 7–8 times along the inside of the cheek for 10 s. After brushing, the swab was
inserted into a tube containing PrimeStore Molecular Transport Medium (PS-MTM), vortexed for 10 s,
and left to stand for 30 min at room temperature. According to the manufacturer, specimens can be
stored for 30 days at ambient temperature (between 2 ◦C and 25 ◦C) or for longer periods if kept frozen
between 0 ◦C and −80 ◦C. Therefore, as samples were processed at the Institut Germans Trias i Pujol in
Spain, samples were stored at room temperature if they would be processed within 30 days, or stored
at −20 ◦C if 30 days passed without having been processed.
DNA was extracted using PrimeXtract total nucleic acid extraction and purification kit (Longhorn
Vaccines and Diagnostics, San Antonio, TX, USA). MTBC DNA was detected by real-time polymerase
chain reaction (RT-PCR, Longhorn’s PrimeMix MTB Multiplex Amplification Solution) which amplifies
the IS6110 and IS1080 regions of the MTBC genome and were conducted using a Lightcycler 480
RT-PCR (Roche, Basel, Switzerland). RT-PCR results were recorded using the endpoint genotyping
call of the Lightcycler 480 software. If both “Allele X” and “Allele Y” are called positive, the assay is
considered positive. If both alleles are called negative, or if the call is labelled “unknown”, the assay
is considered negative. Staff performing the RT-PCR were blinded to the patient information and
previous laboratory tests.
We used Chi Square and Fisher’s exact tests to test differences in proportions and Student’s t-tests
for continuous variables with normal distributions. p-values less than 0.05 were considered statistically
significant. Analysis was performed using SPSS (SPSS version 15.0, SPSS Inc, Chicago, IL, USA).
All subjects gave their informed consent for inclusion before they participated in the study.
The study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved
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by the Ethics Committee of Liverpool School of Tropical Medicine (18-063), “Chiril Draganiuc” Institute
of Phthisiopneumology (8/17 12 June 2017) and Germans Trias i Pujol (PI-16-051).
3. Results
A total of 300 participants were enrolled. Of these, 34 (11.3%) were excluded (3 had initiated
TB treatment, 12 had extrapulmonary TB, 6 had contaminated culture, and 13 had X-rays with scars
considered to be former TB) and 266 were included in the final analysis. The mean (SD) age of the
266 participants was 48.8 (14.4) years and 157 (59.0%) were male. Eighty (30.1%) participants
had positive MTBC culture, of which 69 (86.3%) also had positive GX (Table 1), resulting in
80 bacteriologically-confirmed TB. Thirty four (12.8%) participants had negative laboratory tests
and abnormal X-rays and were considered bacteriologically-negative TB, while 152 (57.1%) had
negative laboratory tests and normal X-rays and were classified as not TB (Table 1). The mean (SD)
ages of patients with bacteriologically-confirmed, bacteriologically-negative and not TB were 45.4
(13.0), 40.9 (16.0) and 52.4 (13.7) years, respectively (p < 0.001). There was a higher proportion of men
and smokers among bacteriologically-confirmed TB participants (Table 1).
Table 1. Demographic characteristics of the 266 participants included in the study.
Bacteriologically
Confirmed TB n = 80
Bacteriologically
Negative TB
n = 34
Not TB
n = 152
Age
Mean ± SD * (48.8 ± 14.4) 45.4 ± 13.0 40.9 ± 16.0 52.4 ± 13.7
Gender
Men (157) 60 (75%) 19 (56%) 78 (51%)
Women (109) 20 (25%) 15 (44%) 74 (49%)
Body mass index
<18.5 (36) 9 (11%) 5 (15%) 22 (14%)
18.5–24.9 (122) 33 (41%) 16 (47%) 73 (48%)
25.0–29.9 (77) 26 (33%) 9 (26%) 42 (28%)
>30 (31) 12 (15%) 4 (12%) 15 (10%)
Smoker
No (121) 22 (28%) 19 (56%) 80 (53%)
Yes (145) 58 (73%) 15 (44%) 72 (47%)
Number of tobacco packs/day
1 (101) 42 (72%) 11 (73%) 48 (67%)
2 (31) 10 (17%) 4 (27%) 17 (24%)
3 (13) 6 (10%) 0 (%) 7 (10%)
Xpert result
Positive 69 (86%) 0 (0%) 0 (0%)
Negative 11 (14%) 34 (100%) 0 (0%)
Not performed 0 (%) 0 (0) 152 (100%)
* SD: standard deviation. TB: Tuberculosis
Overall, 67 (25.2%) oral swabs were RT-PCR-positive and 199 (74.8%) RT-PCR-negative (Table 2).
Fifty-four samples were stored for <30 days and 212 were stored at <30 days and also frozen for
a period ranging from 4 and 7 months. Twenty (37.0%) of 54 samples stored for <30 days were
RT-PCR positive compared with 47 (22.2%) of the 212 samples also stored for 4–7 months (p = 0.03).
Among the 80 patients with bacteriologically-confirmed TB, RT-PCR was positive in 11 (61.1%) of
18 samples stored for <30 days and 18 (29.0%) of 62 samples also stored for 4 to 7 months (p = 0.01)
(Tables 2 and 3). Among the 34 participants with bacteriologically-negative TB, 4 (30.8%) of 13 samples
stored for <30 days and 5 (23.8%) of 21 samples also stored for 4 to 7 months were RT-PCR-positive
(p > 0.5). Among patients with not TB, 18 (78.3%) of 23 samples stored for <30 days and 105 (81.4%) of
129 samples also stored for 4–7 months were RT-PCR-negative (p = 0.46).
J. Clin. Med. 2020, 9, 4124 4 of 7
Table 2. Oral RT-PCR, for the 54 samples stored at room temperature for less than 30 days, and for the 212 samples stored at −20◦C for 4 to 7 months.
RT-PCR Oral Swabs
All Stored < 30 days Also Stored for 4 to 7 Months at −20 ◦C
Positive
n (%)
Negative
n (%) Total
Positive
n (%)
Negative
n (%) Total
Positive
n (%)
Negative
n (%) Total
Bacteriologically confirmed a 29 (36) 51 (64) 80 11 (61) 7 (39) 18 18 (29) 44 (71) 62
Xpert positive 26 (38) 43 (62) 69 10 (71) 4 (29) 14 16 (29) 39 (71) 55
Smear negative 6 (26) 17 (74) 23 2 (50) 2 (50) 4 4 (21) 15 (79) 19
Smear scanty 6 (26) 17 (74) 23 2 (67) 1 (33) 3 4 (20) 16 (80) 20
Smear 1+ 4 (67) 2 (33) 6 - - 0 4 (67) 2 (33) 6
Smear 2+ 3 (75) 1 (25) 4 - - 0 3 (75) 1 (25) 4
Smear 3+ 7 (54) 6 (46) 13 6 (86) 1 (14) 7 1 (17) 5 (83) 6
Xpert negative b 3 (27) 8 (73) 11 1 (25) 3 (75) 4 2 (29) 5 (71) 7
Bacteriologically-negative c 9 (27) 25 (74) 34 4 (31) 9 (69) 13 5 (23.8) 16 (76) 21
Not TB d 29 (19) 123 (81) 152 5 (22) 18 (78) 23 24 (19) 105 (81) 129
Total 67 (25) 199 (75) 266 20 (37) 34 (63) 54 47 (22) 165 (78) 212
a Positive culture, and variable Xpert and smear. b Positive culture, negative Xpert and smear. c Negative culture, Xpert and smear and abnormal X-rays. d Normal X-Rays and negative
culture and smear.
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Table 3. Sensitivity, specificity, positive predictive value and negative predictive value of oral swab RT-PCR by storage conditions.
RT-PCR Oral Swabs Performance
All Samples Stored < 30 Days Also Stored for 4–7 Months at 20 ◦C
Sensitivity
(% (n)
95%CI)
Specificity
(% (n)
95%CI)
Positive
Predictive
Value
(% (95%CI))
Negative
Predictive
Value
(% (95%CI))
Sensitivity
(% (n)
95%CI)
Specificity
(% (n)
95%CI)
Positive
Predictive
Value
(% (95%CI))
Negative
Predictive
Value
(% (95%CI))
Sensitivity
(% (n)
95%CI)
Specificity
(% (n)
95%CI)
Positive
Predictive
Value
(% (95%CI))
Negative
Predictive
Value
(% (95%CI))
Culture 36% (29/80)(26–48)
80%
(148/186)
(73–85)
43% (31–56) 74% (68–80) 61% (11/18)(36–82)
75% (27/36)
(57–87) 55% (32–76) 79% (62–91)
29% (18/62)
(19–42)
81%
(121/150)
(73–86)
38% (25–54) 73% (66–80)
Xpert 40% (26/65)(28–53)
72% (33/46)
(56–84) 67% (50–80) 46% (34–58)
71% (10/14)
(42–90)
67% (12/18)
(41–86) 63% (36–84) 75% (47–92)
29% (16/55)
(18–43)
75% (21/28)
(55–89) 70% (47–86) 35% (23–48)
TB status a
33%
(38/114)
(25–43)
81%
(123/152)
(74–87)
57% (44–69) 62% (55–69) 48% (15/31)(31–67)
78% (18/23)
(56–92) 75% (51–90) 53% (35–70)
28% (23/83)
(19–39)
81%
(105/129)
(73–87)
49% (34–64) 64% (56–71)
a Includes bacteriologically-positive and bacteriologically-negative cases. Specificity estimated considering not tuberculosis (TB) cases as not having TB. CI: confidence interval.
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Among bacteriologically-confirmed TB, 20 (43.5%) of 46 smear-positive and 9 (26.5%) of
34 smear-negative patients were RT-PCR-positive (Table 2). Among the 46 smear positives, eight (80.0%)
of 10 samples stored for <30 days and 12 (33.3%) of 36 also stored for 4–7 months were RT-PCR-positive,
while among the 34 smear-negatives, three (37.5%) of eight samples stored for <30 days (Table 2) and
six (23.1%) of 26 samples also stored for 4–7 months were RT-PCR-positive (Table 2). Three (23.3%) of
11 participants with bacteriologically confirmed TB but negative GX and 9 (26.5%) of 34 participants
with bacteriologically negative TB had positive RT-PCR.
4. Discussion
Our findings demonstrate the feasibility of detecting the presence of MTBC DNA in the oral
mucosa of individuals with TB and suggest that testing oral mucosa for TB has potential additional
diagnostic value for bacteriological confirmation. Oral swabs are easily collected and are not invasive,
and the method would be particularly useful among individuals unable to produce sputum, such as
children and people living with HIV. Currently, the method has lower sensitivity that conventional GX
and culture and further development is needed to assess whether multiple sampling may increase its
sensitivity. Despite the lower sensitivity, we detected MTBC DNA in three individuals with positive
culture but negative GX and in patients with a clinical diagnosis but negative laboratory tests and its
potential as an adjunct test for diagnosis among patients who do not produce sputum is promising.
A few other studies have assessed the use of oral samples for TB diagnosis. A case-control study of
20 GX-positive participants reported that oral swabs tested using an in-house PCR had 73% sensitivity
(87% in smear-positive, 52% in smear-negative) with 100% specificity [3] while a study examining two
oral swabs in children with presumptive pulmonary TB obtained 43% sensitivity and 93% specificity
among bacteriologically confirmed cases [5]. A further study compared the yield of samples collected
from the cheek, tongue and gum [4] and collected single and two consecutive tongue swabs on separate
days. The tongue swabs had a higher yield than swabs from other parts of the mouth and two tongue
swabs resulted in a combined sensitivity of 83% [4]; suggesting that the sample location, the number of
swabs and the time of collection may modify the yield.
Longhorn devices are also suitable to store sputum. Daum et al. reported a sensitivity of 82%
(91% specificity) in PS-MTM stored sputum [7]; while Omar et al. reported 100% and 54% sensitivity
in smear-positive and smear-negative sputum [8]; and Omar et al. reported a sensitivity of 73% and
85% specificity [9]. As sputum would be expected to have higher bacilli numbers that oral samples,
these studies suggest that the lower sensitivity in our study is likely due to lower bacilli numbers.
Our study has limitations that need to be considered. We found that the performance of PS-MTM
may be affected by storage conditions. Although the manufacturer indicates DNA can be preserved,
if stored frozen, stored samples had a lower yield, and therefore, further prospective studies need to
evaluate the time for processing specimens after collection. Patients were also recruited at a reference
laboratory, where the pre-test probability of TB was high. Moreover, participants were only screened
with GX if the patients had abnormal X-Rays or/and TB clinical symptoms. This procedure may have
selected individuals with more advanced TB, who would have been more likely to have cavitations
and higher numbers of bacilli. Moreover, we did not collect information on whether participants had
gargled with oral disinfectants or if they had consumed foods or drinks before sampling, which may
have altered the local amount of bacilli. Altogether, these confounders could have modified the yield
of the diagnostic tests. Furthermore, patients were not followed to document the clinical evolution
of their illnesses and participants initially classified as not TB could have returned later for further
examinations. This latter limitation could explain our lower specificity of the tests compared to other
studies. Unfortunately, we did not include healthy individuals for assessing the specificity. However,
negative control markers were added in each RT-PCR run and were consistently correct. Finally,
although we considered that oral swabs may be useful for children and people with HIV, we did not
test these populations, and further studies are needed.
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In conclusion, MTBC DNA can be detected from samples collected from the oral cavity in a
high proportion of adults with bacteriologically confirmed TB. However, the yield may vary with
sample storage conditions. Oral swabbing is a non-invasive procedure and has potential as an adjunct
diagnosis for TB and further studies are needed to document its yield in children and individuals with
low bacilli load, such as people living with HIV.
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